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Abstract This study examined the reliability and validity of a new measure for evaluating symptoms in patients with 
chronic obstructive pulmonary disease (COPD): the Breathlessness, Cough and Sputum Scale (BCSS©). Designed as a daily 
diary, the BCSS is a patient-reported outcome measure that asks patients to rate the severity of the three symptoms, each 
on a 5-point scale; higher scores indicate more severe symptoms. Item scores are summed to yield a total score. 
Secondary analysis of data were from two multinational trials (n=629; 765). 
The BCSS item and total scores exhibited evidence of internal consistency (oc = 0.70 daily; 0"95 to 0.99 over time) and 
reproducibility (ICC = 0"77 to 0'88). Correlations (r) with pulmonary function (FEV 1% predicted, PEF) were -0"01 (n.s.) 
to -0"36 (P < 0.001). Correlations with the St George's Respiratory Questionnaire total and SF-36 Physical Functioning 
subscale were 0.44to0-59 (P<0.001). Breathlessness and total scores differentiated patients by disease severity 
(P < 0"0 I) and rescue medication use (P < 0"0 I). Cough, sputum, and total scores increased with sputum volume (r=0-27, 
0.30, 0.3 I; P < 0.001). Patients for whom treatment was moderately or highly effective reported significant improvements 
in BCSS scores (P < 0.0001). 
Results suggest that the BCSS is a reliable, valid, and responsive patient-reported outcome measure of symptom severity 
in patients with COPD. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) refers 
to a cluster of diseases (including chronic bronchitis and 
emphysema) in which patients experience progressive 
reduction in expiratory airflow with symptoms of 
breathlessness, cough, and sputum production. Although 
pulmonary function is an important objective marker of 
the degree of airway obstruction, the patient's self-report 
of the severity of these symptoms is key to successfully 
monitoring disease activity, adjusting treatment, and 
evaluating outcomes (I). There are surprisingly few 
instruments to assess symptom severity and symptom 
outcomes in this population. The Baseline Dyspnoea 
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Index (BDI)/Transition Dyspnoea Index (TDI) (2), 
modified Medical Research Council (MRC) Dyspnoea 
Scale (3), Oxygen Cost Diagram (4) and Borg Scale (5) 
have been used to evaluate breathlessness, but do not 
address cough or sputum.The length and 3-month recall 
period of the Chronic Lung Disease Severity Index (6) is 
not conducive to evaluating treatment outcomes in 
short-term clinical trials. Condition-specific health- 
related quality of life (HRQL) measures, such as the St 
George's Respiratory Questionnaire (SGRQ) (7) or the 
Chronic Respiratory Questionnaire (CRQ) (8), assess 
the impact of symptoms on daily functioning and well- 
being rather than symptom severity per se.To date, there 
has been no published, validated (reliable, valid, 
responsive) measure to assess day-to-day symptom 
severity in COPD. 
The purpose of this study was to assess the reliability, 
validity, and responsiveness of the Breathlessness, Cough 
and Sputum Scale (BCSS©). The BCSS is a patient- 
reported outcome measure that was designed as a daily 
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diary in which subjects are asked to record the severity 
of three symptoms of COPD: breathlessness, cough, and 
sputum (AppendixA). Each symptom is represented by a 
single item which is evaluated on a 5-point Likert-type 
scale ranging from 0 to 4, with higher scores indicating a 
more severe manifestation of the symptom.Total score is 
expressed as the sum of three item scores, with a range 
of 0 to 12. Weekly and period (baseline, treatment, 
follow-up) scores can be computed by aggregating daily 
scores over time. 
METHODS 
Design 
This study used secondary analyses of blinded data from 
two multicentre, multinational, randomized, double-blind, 
placebo-controlled clinical trials evaluating the safety and 
efficacy of AR-C68397AA (Viozan TM, sibenadet HCI), a 
novel dual dopamine D2-receptor/132-adrenoreceptor 
agonist for use in patients with COPD (9-14). Both trials 
involved a 7- to 14-day baseline period followed by 
4 (trial I) or 6 (trial 2) weeks of treatment. The data 
analysis plan was formulated by the first two authors 
(NKL, JKS) based on the study protocols before receiving 
the data; these authors performed the analyses and were 
blind to treatment hroughout the evaluation. 
Study subjects 
Patient selection criteria were similar in both trials. All 
patients were between 45 and 70 years of age with a 
medical diagnosis of COPD = 2 years, a smoking history, 
and a per cent predicted forced expiratory volume in one 
second (FEV 1% predicted) between 20% and 70%. Exclusion 
criteria included a complicating comorbid condition or 
need for domiciliary oxygen. In trial 2, patients must have 
recorded a BCSS total score of 2 or more on 
7consecutive days during the baseline period. The 
research protocols were approved by the appropriate 
institutional review boards, and all patients gave written 
informed consent prior to enrolment in the trial. 
Measures 
Clinical assessments 
Baseline FEV 1% predicted, peak expiratory flow (PEF), 
rescue medication use, and sputum volume were used as 
clinical indicators for assessing the construct validity of 
the BCSS. Evening PEF values (Mini-Wright ~ PEF meter) 
and rescue medication use during the previous 24 hours 
were recorded by patients each day in a diary. For the 
purposes of these analyses, these values were expressed 
as the mean daily PEF value and mean number of 
actuations per day during the baseline period. Sputum 
volume was gathered in trial I, during the last 24 hours 
of the baseline period. 
Symptoms and Health-Related Quality of Life 
The modified Borg scale was used ~to assess 
breathlessness prior to spirometry at baseline in trial I 
(I 5). Specifically, patients were asked to describe their 
level of dyspnoea on a scale ranging from 0, indicating 
'nothing at all', to 10, indicating 'maximal impairment'. 
The SGRQ, a condition-specific HRQL measure, was 
used to evaluate the validity of the BCSS.The instrument 
consists of 76items and three subscales (Symptoms, 
Activity, and Impacts [on daily life]) that can be 
aggregated to yield a total score. Seven of the items 
address activity-related yspnoea (Part 2, Section 2), and 
four items address cough (Part 2, Section 3, 4). Subscale 
and total scores range from 0 to 100, with higher scores 
indicating poorer HRQL (16).The SGRQ has been used 
widely in research involving patients with COPD 
(7,16-24). It has been suggested that a change of 4.0 or 
greater in SGRQ total score be considered clinically 
meaningful (I 6). 
The Medical Outcomes Study Short-Form 36 Health 
Survey (SF-36), a generic HRQL measure, was also used 
to validate the BCSS (data gathered in trial I only).This 
36-item measure comprises eight subscales that can be 
aggregated into two summary scores: the Physical 
Component Summary (PCS) and the Mental Component 
Summary (MCS) (24,25). Scores range from 0to 100, 
with higher scores indicating better HRQL.The SF-36 is 
widely used to evaluate burden of illness and outcomes 
of treatment in a variety of health conditions, including 
COPD (2,26-33), and is often used to assess construct 
validity of newly developed patient outcome measures. 
Analyses 
Unless otherwise specified, baseline data were used in 
the analyses. 
Missing data and distributional characteristics 
The rate of missing data and the distributional properties 
of the BCSS scores were examined first. Of particular 
interest were floor (the number and percentage of 
patients reporting the lowest possible score on the 
measure) and ceiling (number and percentage of patients 
reporting the highest possible score; worst symptoms 
possible) effects. These values indicate the extent to 
which an instrument is capable of detecting symptomatic 
improvement or deterioration (respectively) over time 
or with treatment. 
Reliability 
The measurement error associated with the BCSS was 
examined by assessing its internal consistency and 
reproducibility (test-retest reliability). The internal 
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consistency reliability of the daily BCSS total score and 
total and item scores aggregated over time were 
assessed using the Cronbach's formula for coefficient 
alpha (0c). 
Reproducibility of scores from baseline to treatment was 
assessed using the intraclass correlation coefficient 
(random-effects model), with Pearson product-moment 
correlations and mean score differences used to further 
assess score stability. These analyses were performed 
across treatment groups in a subsample of patients for 
whom both physician and patient agreed that the treatment 
produced no change or was only mildly effective. 
Validity 
Pearson product-moment correlations between BCSS 
scores and FEV 1% predicted, evening PEF, sputum 
volume (trial 2) and HRQL (SGRQ and SF-36 [trial I]) 
were used to assess the construct validity of the BCSS. 
Correlations between the BCSS and the Symptom 
subscale of the SGRQ, dyspnoea- and cough-specific 
items from the SGRQ, and the Borg scale (trial I) were 
used to assess the measure's concurrent, convergent and 
divergent validity. 
The BCSS was also subjected to two tests of 
discriminant validity.Analysis of variance (ANOVA) with 
post hoc Scheff~ test was used to test the extent to which 
BCSS scores varied by level of disease severity (35,36). 
The Student's t-test was used to compare BCSS scores 
for patients in the lower 25 th and upper 25 th percentile 
of rescue medication use.The primary concern in these 
analyses was the performance of the Breathlessness item 
of the BCSS, although the discriminant validity of the 
Cough, Sputum and total scores was also assessed. 
Responsiveness 
The responsiveness (sensitivity) of the BCSS to within- 
group change (symptom improvement) and between- 
group differences (improved vs. stable) was also 
examined using the paired t-test and Student's t-test, 
respectively. Data were analysed across treatment group 
in a subsample of patients categorized as improved based 
on patient and physician agreement hat treatment was 
moderately or highly effective.The method for identifying 
stable patients was described previously. 
Exploratory analyses 
Three alternative methods for assessing symptom 
outcomes in COPD using BCSS diary data were also 
examined: symptom-free days (a score of 0 on BCSS 
total score), symptom relief ('good') days (0 or I on each 
BCSS item), and easy ('EZ') breathing days 
(Breathlessness score of 0or  I, regardless of other 
symptoms). 'Good' and 'EZ' breathing days would offer 
two new methods for evaluating symptom outcomes in 
COPD. Because results from the two trials were 
comparable for these exploratory measures, only results 
from analyses of data from trial I are presented. 
Significance testing and interpretation 
All statistical analyses were conducted using Statistical 
Analysis Software (SAS) version 6.12 (SAS Institute, 
Cary, NC), a significance level of 0-05, and 2-tailed tests. 
Because this was a psychometric evaluation, no 
adjustments were made for multiple comparisons. 
Correlation coefficients (r) and effect size estimates for 
within- and between-group differences were interpreted 
using guidelines proposed by Cohen (36), in which + 0" I 0 
is considered small, ± 0"30 moderate, and + 0-50 large.To 
assist in interpretation of change scores, data were 
examined for convergence between mean change in 
BCSS total and item scores, per cent change, statistical 
effect size and change in HRQL. 
RESULTS 
Sample 
Demographic and clinical characteristics of the two 
study populations used in this analysis are presented in 
Table I. Across trial populations, most subjects were 
male, mean FEV 1% predicted was less than 45%, and 
mean duration of COPD was greater than 5 years. 
Missing data and distributional 
characteristics 
Missing data for patients who did not withdraw from the 
trial was less than 5% across all days. Mean baseline BCSS 
total scores were 4.14 + 2.20 and 5.09 ± 1.99 in the two 
studies. The distribution was near normal, with median 
values of 4 and 5 and modes of 3 and 6, respectively. 
Although the distribution fell on the low half of the 
13-point scale, floor effects were small (< 2%), indicating 
symptomatic improvement could be detected.The small 
ceiling effects (< I% of the patients reported the highest 
score possible) also indicate there is room for score 
movement with increases in symptom severity. 
Of the three items, Breathlessness mean scores were 
the highest (trial I: 1.7 ± 0.9; trial 2:2-0 ± 0.7), followed 
by Cough (I .4 ± 0.9; 1.7 + 0"9) and Sputum (I. 10 + 0"88; 
1.37 ± 0-87). Floor effects were lowest for the 
Breathlessness item (8%; I%), followed by Cough (9%; 
4%) and Sputum ( 19%; 12%). 
Reliability 
Internal consistency levels (~) of the day-to-day BCSS 
total score during the baseline and treatment periods 
ranged from 0-70 to 0.76 in trial I and from 0"68 to 0-80 
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in trial 2 (data not shown).The range of ~ levels for BCSS 
scores over the baseline period ranged from 0.94 to 0.97 
(Table 2). 
Intraclass correlation coefficients for the BCSS total 
score ranged from 0-77to0.78 (Table2). Pearson 
product-moment correlation coefficients were similar. 
BCSS total scores changed from 4. I (± 2.2) during the 
baseline period to 3"7 (± 2.0) during treatment in trial I 
(9% change, effect size of 0" 12) and from 5"0 (± 1.9) at 
baseline to 4.9 (± 1.9) during treatment in trial 2 (3% 
change; effect size = -0-07). 
Validity 
Pearson product-moment correlation coefficients testing 
the construct and concurrent validity of the BCSS are 
shown in Tables 3 and 4. Correlations between the BCSS 
scores, FEV 1% predicted and PEF were in the predicted 
direction and small to moderate in magnitude, with the 
Breathlessness score the strongest correlate (Table 3). 
Correlations between the BCSS and sputum volume 
were also in the predicted direction, with Sputum score 
the strongest correlate. Sputum volumes by BCSS item 
responses for the same 24-hour period are shown in 
Figure la,b,c. Patients recording high scores on the 
Breathlessness, Cough, or Sputum items during this time 
period (scores of 3 or4) produced significantly more 
sputum than those reporting little or no symptom 
difficulty (scores of 0 or I; P < 0.05, P < 0-0001, and 
P < 0"000 I, respectively). 
Correlations between BCSS total and item scores and 
SGRQ total, Activity, and Impacts scores, tests of 
construct validity, were moderate and statistically 
significant, with the strongest correlations between BCSS 
and SGRQ total scores (Table4). The relationships 
between BCSS total and item scores and the generic 
SF-36 were also in the predicted direction, small to 
moderate in magnitude, and statistically significant. 
Correlations between BCSS scores and Symptoms 
subscale, dyspnoea- and cough-specific scores from the 
SGRQ and the modified Borg scale (trial I) indicate 
concurrent validity and provide data on the convergent 
and divergent validity of the three items comprising the 
BCSS. Correlations between the BCSS and the SGRQ 
Symptoms subscale were statistically significant, 
moderate to large in magnitude, and consistent across 
the two trials (Table 3). The correlation between the 
Breathlessness score and Borg scale score was also 
moderate (Table 3); the fact that this relationship was 
stronger than the correlation between the Borg scale 
score and either Cough or Sputum scores is evidence of 
the convergent and divergent validity of the BCSS. 
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Similar results were observed with dyspnoea- and 
cough-specific items from the SGRQ (Table3). 
Correlations between the dyspnoea-specific item scores 
from the SGRQ and BCSS Breathlessness item were 
moderate and stronger than correlations between these 
SGRQ item scores and the BCSS Cough or Sputum 
scores. Similarly, correlations between cough-specific 
item scores from the SGRQ and BCSS Cough scores 
were stronger than correlations between the SGRQ 
Cough item scores and BCSS Breathlessness score. SGRQ 
Cough scores also correlated with the BCSS Sputum 
score. 
Mean BCSS total scores increased as disease severity 
(FEV 1% predicted, American Thoracic Society severity 
classification (34) increased (Figure 2).The Breathlessness 
score exhibited the strongest evidence of discriminant 
validity, differentiating among the four severity groups in 
both trials (F=7.03, R2=0.04, P < 0.001; F-20.61, R2=0 • 10, 
P < 0.001, respectively; data not shown). Results were 
similar using the European Respiratory Society severity 
classification (35),with mean BCSS total scores increasing 
as disease severity increased (from 3-6 to 4.3 in trial I 
[F=2.53, R2=0-0 I, P < 0.09] and from 4.6 to 5.3 in trial 2 
[F=6.45, R2=0.02, P < 0.01 ]). 
The BCSS total score was also able to discriminate 
between high and low rescue medication use in both 
data sets (Figure3). The BCSS Breathlessness score 
differentiated the two groups (t=-3.26, P< 0.01; 
t=-10.28, P<0"0001) as did Sputum score (t=-2.34, 
P < 0"05; -3.65, P < 0.001). The BCSS Cough scores 
differentiated the groups in trial 2 only (t=-2.91, 
P < 0-0 I; data not shown). 
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FIGURE I. Mean sputum volume (£ SD) by BCSS response option; (a) breathlessness, (b) cough and (c) sputum. 
Responsiveness 
Significant improvements in BCSS total and item scores 
were observed for patients categorized as having 
improved during the course of treatment (Figure4). 
Patients in the 'improved' group reported significant 
improvement in BCSS total and item scores from 
baseline to the end of treatment, with scores significantly 
better than those of the stable group. With the 
exception of the Sputum score in trial I, all between- 
group differences (improved vs. stable patients) were 
statistically significant. 
To facilitate the interpretation of changes in BCSS 
scores, data were examined for points of convergence 
between mean change, per cent change, and statistical 
effect size for BCSS scores and change in HRQL 
(Table 5). In trial I, the mean score change o f - I "  I on the 
BCSS total score corresponded to 28% improvement in 
symptom severity and a moderate to large effect size. 
For patients with HRQL data, the mean improvement in 
SGRQ total score exceeded the guideline of 4.0, 
indicating a clinically meaningful change. In trial 2, the 
mean change in BCSS total score of-0"9 corresponded 
to an 18% improvement and a moderate to large effect 
size, and the mean change in SGRQ total score exceeded 
the guideline for clinically meaningful change. 
Exploratory analyses 
Patients who improved during trial l experienced 
significantly more symptom-free days than patients who 
were stable during the 28-day treatment period 
(5.7 + 8.5 vs. 2" I + 5.9 days; P < 0.05).These patients also 
experienced significantly more symptom-relief ('good') 
days (16.1 + 11.2 vs. 10.6 + 10.8) and'EZ' breathing days 
(18.7+ 10.6 vs. 13.4+ 11.3;P<0.05). 
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DISCUSSION 
This secondary analysis examined the distributional 
properties, reliability, validity, and responsiveness of the 
BCSS, a new three-item measure for evaluating the 
severity of three symptoms associated with COPD: 
breathlessness, cough and sputum. The distribution of 
BCSS scores was near normal, with low floor and ceiling 
effects, indicating the measure is capable of detecting 
improvement or deterioration in symptoms. Internal 
consistency reliability levels of the daily BCSS total score 
exceeded the recommended criterion of 0-70 
considered sufficient for predictive or construct 
validation research (13). Internal consistency levels over 
time exceeded the 0"80 criterion for experimental 
research and the standard of 0.95 when individual-level 
data are being used for decision-making purposes (37). 
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FIGURE 4. Mean BCSS change score by change group (improved vs. stable): within-group and between-group differences. 
Reproducibility estimates for the BCSS suggest scores 
are replicable with values meeting or exceeding values 
reported for measures such as the Symptoms subscale of 
the SGRQ (21,38,39). 
The validity of the BCSS was evaluated by examining 
the relationship between the item and total scores and 
FEV 1% predicted, PEF, sputum volume, modified Borg 
scale, and indicators of HRQL, including the specific 
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impact of cough and dyspnoea. Results suggest the BCSS 
item scores are valid indicators of the severity of patient 
breathlessness, cough and sputum, respectively. 
Correlations between FEV 1% predicted and the BCSS 
Breathlessness score were small to moderate in 
magnitude and consistent with correlations between 
FEV 1% predicted and BDI and CRQ Dyspnoea subscale 
score (r=0.31 and 0.35, respectively) reported by Hajiro 
etal. (21) and with the MRC dyspnoea scale score 
(Spearman p=0.37) reported by Eltayara et al. (3). 
One of the advantages of the BCSS is the simultaneous 
inclusion of breathlessness, cough and sputum 
assessments. Results suggest BCSS scores are valid 
indicators of the severity of cough and sputum in 
patients with COPD. Scores for both items were 
correlated with sputum volume. Patients who reported 
'severe' cough and sputum (scores of 3 or 4) produced 
significantly more sputum than those reporting little or 
no symptom difficulty (scores of 0 or I). Scores on these 
items also correlated with cough-specific HRQL items 
from the SGRQ. 
Correlations between the BCSS total scores and 
indicators of HRQL suggest hat the BCSS total score is a 
valid summary indicator of symptom severity. Correlations 
between the SGRQ Symptom and BCSS total scores were 
similar to reported correlations between this SGRQ 
subscale and resting Borg (r=0.43) (40) and the Oxygen 
Cost Diagram (r=0.46) (41) and larger than correlations 
between SGRQ symptoms score and daily assessments of 
dyspnoea (r=0.27), sputum (r=0.30) and bronchitic 
symptoms (r=0"26) (42). The BCSS total score also 
increased as the degree of airway obstruction increased 
and discriminated between high and low rescue 
medication users. These associations suggest that the 
measure is sensitive to variation in disease severity. 
Results of this study also suggest hat the BCSS total 
and item scores are sensitive to within-group change and 
between-group differences. Patients in the 'improved' 
group experienced 5 more 'good' days and over 5 more 
'EZ' breathing days during the 28-day treatment period 
than those in the stable group. This suggests that the 
daily diary approach may offer a new method for 
understanding symptomatic improvement in the COPD 
population in terms of number of 'good' and 'EZ' 
breathing days gained with treatment. Based on per cent 
change, effect size, mean HRQL changes and the number 
of 'good' days observed in the improved patients, the 
mean change of + I point on the BCSS total score 
appears to be a substantial improvement in symptom 
severity for patients with moderate to severe COPD. 
The BCSS was designed to evaluate the severity of 
three symptoms associated with COPD: breathlessness, 
cough, and sputum. Results of this study suggest that the 
BCSS is reliable, valid and responsive to change. 
Information about an instrument's reliability and validity 
accrues over time, and confidence in the instrument 
increases as it is used in repeated investigations by 
various scientists and in diverse conditions and settings. 
Results of these secondary analyses indicate that further 
use of this patient-reported outcome measure as a 
clinical tool and outcome measure in intervention 
studies involving patients with COPD is warranted. 
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